Synaptic vesicle protein 2 isoforms and gangliosides on motor neuron (SV2 (for synaptic vesicle protein 2); none standard for gangliosides as a group)

Synaptic vesicle protein 2 (SV2) refers to a family of integral neuronal vesicle glycoproteins (SV2A, SV2B, SV2C) that regulate action potential-dependent neurotransmitter release by modulating vesicle trafficking and synaptotagmin expression[1][3][5][7]. SV2A in particular is a validated therapeutic target for antiepileptic drugs (levetiracetam, brivaracetam) and is widely expressed in the CNS, with isoform-specific regional patterns. SV2 is also involved in the neuronal entry of neurotoxins, such as tetanus toxin[7]. Gangliosides are sialic acid–containing glycosphingolipids concentrated in neural membranes, particularly at synaptic sites. They orchestrate membrane stability, modulate receptor signaling, and play critical roles in neuronal development, myelination, neuroprotection, and repair. Individual gangliosides (e.g., GM1, GD1a, GT1b) interact with protein receptors (such as TrkA and MAG), influence neuronal survival, and regulate axon outgrowth and regeneration[6][2][4][8]. Abnormal ganglioside metabolism or expression is linked to various neurodevelopmental and neurodegenerative diseases, as well as autoimmune syndromes involving antiganglioside antibodies[4][8].

Other names

SV2ASV2BSV2CGM1GD1aGD1bGT1bGM3GD3

Modulation of neurotransmitter release via interaction with synaptotagmin and regulation of calcium-dependent exocytosis; neuronal entry point for certain neurotoxins (e.g., tetanus toxin). Modulation of neurotrophin signaling (e.g., TrkA receptor), membrane microdomain organization, inhibition of axon outgrowth (via MAG interaction), neuroprotection.